Biogen Inc. (LON:0R1B)
149.78
+0.95 (0.64%)
At close: Oct 24, 2025
Biogen Revenue
Biogen had revenue of $2.65B USD in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
2.26
Revenue / Employee
$1.31M
Employees
7,605
Market Cap
16.52B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Biogen News
- 23 hours ago - Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease - GlobeNewsWire
- 3 days ago - Biogen's Immunology Pipeline Has Long-Term Potential: Analyst - Benzinga
- 3 days ago - Biogen (BIIB) Secures Licensing Deal for Immunology Candidate - GuruFocus
- 3 days ago - Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key - Nasdaq
- 3 days ago - Biogen, Vanqua ink licensing deal worth up to $1B for immunology drug - Seeking Alpha
- 3 days ago - Biogen (BIIB) Secures Global Rights in $1.06 Billion Deal with Vanqua - GuruFocus
- 3 days ago - Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion - Reuters
- 3 days ago - Biogen Inks License Deal For Vanqua Bio's Oral C5aR1 Antagonist - Nasdaq